New Zealand markets closed

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (9989.HK)

HKSE - HKSE Delayed price. Currency in HKD
Add to watchlist
3.300+0.080 (+2.48%)
As of 01:44PM HKT. Market open.
Currency in HKD

Valuation measures4

Market cap (intra-day) 12.44B
Enterprise value 15.06B
Trailing P/E 16.33
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)0.80
Price/book (mrq)0.36
Enterprise value/revenue 2.54
Enterprise value/EBITDA 32.53

Trading information

Stock price history

Beta (5Y monthly) 0.43
52-week change 3-25.98%
S&P500 52-week change 324.43%
52-week high 34.500
52-week low 32.390
50-day moving average 33.328
200-day moving average 33.387

Share statistics

Avg vol (3-month) 3716.02k
Avg vol (10-day) 3362.15k
Shares outstanding 5220.09M
Implied shares outstanding 63.86B
Float 8457.64M
% held by insiders 111.75%
% held by institutions 11.26%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 40.11
Forward annual dividend yield 43.27%
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 468.21%
Dividend date 3N/A
Ex-dividend date 424 May 2023
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in CNY.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin -12.59%
Operating margin (ttm)18.68%

Management effectiveness

Return on assets (ttm)-0.43%
Return on equity (ttm)-5.80%

Income statement

Revenue (ttm)5.52B
Revenue per share (ttm)3.76
Quarterly revenue growth (yoy)5.60%
Gross profit (ttm)N/A
EBITDA 201.85M
Net income avi to common (ttm)-694.76M
Diluted EPS (ttm)-0.510
Quarterly earnings growth (yoy)133.00%

Balance sheet

Total cash (mrq)2.5B
Total cash per share (mrq)1.71
Total debt (mrq)4.94B
Total debt/equity (mrq)40.74%
Current ratio (mrq)2.26
Book value per share (mrq)8.22

Cash flow statement

Operating cash flow (ttm)1.49B
Levered free cash flow (ttm)1.15B